DIPG-70. NQO1 AS A RESISTANCE DRIVER AND THERAPEUTIC TARGET IN DMG
p53 pathway reactivation through pharmacologic inhibition of negative regulators was identified as a promising therapeutic strategy for TP53 wild-type (WT) high-grade gliomas, including Diffuse Midline Gliomas (DMGs). Despite widespread theoretical promise, the therapeutic efficacy of MDM2 inhibitor...
Gespeichert in:
| Veröffentlicht in: | Neuro-oncology (Charlottesville, Va.) Va.), 2024-06, Vol.26 (Supplement_4), p.0-0 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 0 |
|---|---|
| container_issue | Supplement_4 |
| container_start_page | 0 |
| container_title | Neuro-oncology (Charlottesville, Va.) |
| container_volume | 26 |
| creator | Lupien, Leslie E Morin, Eric Zhang, Daren F Novikov, Dana R Chacon, Madison S Khuu, Nicholas Keshishian, Hasmik Seidel, Olivia Carr, Steven A Goodale, Amy Persky, Nicole S Root, David E Cusick, Margaret Ligon, Keith L Beroukhim, Rameen Phoenix, Timothy M Rendo, Veronica Bandopadhayay, Pratiti |
| description | p53 pathway reactivation through pharmacologic inhibition of negative regulators was identified as a promising therapeutic strategy for TP53 wild-type (WT) high-grade gliomas, including Diffuse Midline Gliomas (DMGs). Despite widespread theoretical promise, the therapeutic efficacy of MDM2 inhibitors and PPM1D inhibitors as single agents have each been limited by issues, including sub-lethal effects on cancer cells and innate or emerging resistance leading to tumor progression. We carried out a genome-scale CRISPR activating (CRISPRa) screen to identify genes that, when overexpressed, confer resistance to p53 reactivation therapies. NAD(P)H quinone dehydrogenase 1 (NQO1) emerged as a top hit and was confirmed through secondary CRISPRa screens and low-throughput validations as driving a resistance phenotype in TP53 WT DMGs. Our subsequent work has aimed to elucidate the mechanisms through which NQO1 mediates the effects of p53 reactivation therapies, and assess the feasibility and impact of exploiting NQO1 in combination therapies towards a cure. |
| doi_str_mv | 10.1093/neuonc/noae064.123 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11182908</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_11182908</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1433-f8d9a062f0d8b2f0cf32758f603da6c80c33bb078b55aa53e282f03d65823ad3</originalsourceid><addsrcrecordid>eNpVkMtOwzAQRS0EEqXwA6z8A2n9qB13hUxi0kglLYlhazmOA0VtUiUUib8n0AqJzdyRZu5ZHABuMZpgNKfTxh_axk2b1nrEZxNM6BkYYUZowATn5787CQTD4SW46vt3hAhmHI_AfZyukyBEE5g9rTCUBZQwV0VaaJlFCsZ5-qJyKLMY6oXK5Vo96zSCWuaJ0jDNYPyYXIOL2m57f3PKMdAPSkeLYLlK0kguA4dnlAa1qOYWcVKjSpTDdDUlIRM1R7Sy3AnkKC1LFIqSMWsZ9UQMX7TiTBBqKzoGd0fs_lDufOV889HZrdl3m53tvkxrN-b_pdm8mdf202CMBZkjMRDIkeC6tu87X_-VMTI_Gs1RozlpNING-g3KGmMb</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>DIPG-70. NQO1 AS A RESISTANCE DRIVER AND THERAPEUTIC TARGET IN DMG</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Lupien, Leslie E ; Morin, Eric ; Zhang, Daren F ; Novikov, Dana R ; Chacon, Madison S ; Khuu, Nicholas ; Keshishian, Hasmik ; Seidel, Olivia ; Carr, Steven A ; Goodale, Amy ; Persky, Nicole S ; Root, David E ; Cusick, Margaret ; Ligon, Keith L ; Beroukhim, Rameen ; Phoenix, Timothy M ; Rendo, Veronica ; Bandopadhayay, Pratiti</creator><creatorcontrib>Lupien, Leslie E ; Morin, Eric ; Zhang, Daren F ; Novikov, Dana R ; Chacon, Madison S ; Khuu, Nicholas ; Keshishian, Hasmik ; Seidel, Olivia ; Carr, Steven A ; Goodale, Amy ; Persky, Nicole S ; Root, David E ; Cusick, Margaret ; Ligon, Keith L ; Beroukhim, Rameen ; Phoenix, Timothy M ; Rendo, Veronica ; Bandopadhayay, Pratiti</creatorcontrib><description>p53 pathway reactivation through pharmacologic inhibition of negative regulators was identified as a promising therapeutic strategy for TP53 wild-type (WT) high-grade gliomas, including Diffuse Midline Gliomas (DMGs). Despite widespread theoretical promise, the therapeutic efficacy of MDM2 inhibitors and PPM1D inhibitors as single agents have each been limited by issues, including sub-lethal effects on cancer cells and innate or emerging resistance leading to tumor progression. We carried out a genome-scale CRISPR activating (CRISPRa) screen to identify genes that, when overexpressed, confer resistance to p53 reactivation therapies. NAD(P)H quinone dehydrogenase 1 (NQO1) emerged as a top hit and was confirmed through secondary CRISPRa screens and low-throughput validations as driving a resistance phenotype in TP53 WT DMGs. Our subsequent work has aimed to elucidate the mechanisms through which NQO1 mediates the effects of p53 reactivation therapies, and assess the feasibility and impact of exploiting NQO1 in combination therapies towards a cure.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noae064.123</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Final category: Diffuse Midline Glioma, Diffuse Intrinsic Pontine Glioma</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (Supplement_4), p.0-0</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids></links><search><creatorcontrib>Lupien, Leslie E</creatorcontrib><creatorcontrib>Morin, Eric</creatorcontrib><creatorcontrib>Zhang, Daren F</creatorcontrib><creatorcontrib>Novikov, Dana R</creatorcontrib><creatorcontrib>Chacon, Madison S</creatorcontrib><creatorcontrib>Khuu, Nicholas</creatorcontrib><creatorcontrib>Keshishian, Hasmik</creatorcontrib><creatorcontrib>Seidel, Olivia</creatorcontrib><creatorcontrib>Carr, Steven A</creatorcontrib><creatorcontrib>Goodale, Amy</creatorcontrib><creatorcontrib>Persky, Nicole S</creatorcontrib><creatorcontrib>Root, David E</creatorcontrib><creatorcontrib>Cusick, Margaret</creatorcontrib><creatorcontrib>Ligon, Keith L</creatorcontrib><creatorcontrib>Beroukhim, Rameen</creatorcontrib><creatorcontrib>Phoenix, Timothy M</creatorcontrib><creatorcontrib>Rendo, Veronica</creatorcontrib><creatorcontrib>Bandopadhayay, Pratiti</creatorcontrib><title>DIPG-70. NQO1 AS A RESISTANCE DRIVER AND THERAPEUTIC TARGET IN DMG</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>p53 pathway reactivation through pharmacologic inhibition of negative regulators was identified as a promising therapeutic strategy for TP53 wild-type (WT) high-grade gliomas, including Diffuse Midline Gliomas (DMGs). Despite widespread theoretical promise, the therapeutic efficacy of MDM2 inhibitors and PPM1D inhibitors as single agents have each been limited by issues, including sub-lethal effects on cancer cells and innate or emerging resistance leading to tumor progression. We carried out a genome-scale CRISPR activating (CRISPRa) screen to identify genes that, when overexpressed, confer resistance to p53 reactivation therapies. NAD(P)H quinone dehydrogenase 1 (NQO1) emerged as a top hit and was confirmed through secondary CRISPRa screens and low-throughput validations as driving a resistance phenotype in TP53 WT DMGs. Our subsequent work has aimed to elucidate the mechanisms through which NQO1 mediates the effects of p53 reactivation therapies, and assess the feasibility and impact of exploiting NQO1 in combination therapies towards a cure.</description><subject>Final category: Diffuse Midline Glioma, Diffuse Intrinsic Pontine Glioma</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkMtOwzAQRS0EEqXwA6z8A2n9qB13hUxi0kglLYlhazmOA0VtUiUUib8n0AqJzdyRZu5ZHABuMZpgNKfTxh_axk2b1nrEZxNM6BkYYUZowATn5787CQTD4SW46vt3hAhmHI_AfZyukyBEE5g9rTCUBZQwV0VaaJlFCsZ5-qJyKLMY6oXK5Vo96zSCWuaJ0jDNYPyYXIOL2m57f3PKMdAPSkeLYLlK0kguA4dnlAa1qOYWcVKjSpTDdDUlIRM1R7Sy3AnkKC1LFIqSMWsZ9UQMX7TiTBBqKzoGd0fs_lDufOV889HZrdl3m53tvkxrN-b_pdm8mdf202CMBZkjMRDIkeC6tu87X_-VMTI_Gs1RozlpNING-g3KGmMb</recordid><startdate>20240618</startdate><enddate>20240618</enddate><creator>Lupien, Leslie E</creator><creator>Morin, Eric</creator><creator>Zhang, Daren F</creator><creator>Novikov, Dana R</creator><creator>Chacon, Madison S</creator><creator>Khuu, Nicholas</creator><creator>Keshishian, Hasmik</creator><creator>Seidel, Olivia</creator><creator>Carr, Steven A</creator><creator>Goodale, Amy</creator><creator>Persky, Nicole S</creator><creator>Root, David E</creator><creator>Cusick, Margaret</creator><creator>Ligon, Keith L</creator><creator>Beroukhim, Rameen</creator><creator>Phoenix, Timothy M</creator><creator>Rendo, Veronica</creator><creator>Bandopadhayay, Pratiti</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20240618</creationdate><title>DIPG-70. NQO1 AS A RESISTANCE DRIVER AND THERAPEUTIC TARGET IN DMG</title><author>Lupien, Leslie E ; Morin, Eric ; Zhang, Daren F ; Novikov, Dana R ; Chacon, Madison S ; Khuu, Nicholas ; Keshishian, Hasmik ; Seidel, Olivia ; Carr, Steven A ; Goodale, Amy ; Persky, Nicole S ; Root, David E ; Cusick, Margaret ; Ligon, Keith L ; Beroukhim, Rameen ; Phoenix, Timothy M ; Rendo, Veronica ; Bandopadhayay, Pratiti</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1433-f8d9a062f0d8b2f0cf32758f603da6c80c33bb078b55aa53e282f03d65823ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Final category: Diffuse Midline Glioma, Diffuse Intrinsic Pontine Glioma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lupien, Leslie E</creatorcontrib><creatorcontrib>Morin, Eric</creatorcontrib><creatorcontrib>Zhang, Daren F</creatorcontrib><creatorcontrib>Novikov, Dana R</creatorcontrib><creatorcontrib>Chacon, Madison S</creatorcontrib><creatorcontrib>Khuu, Nicholas</creatorcontrib><creatorcontrib>Keshishian, Hasmik</creatorcontrib><creatorcontrib>Seidel, Olivia</creatorcontrib><creatorcontrib>Carr, Steven A</creatorcontrib><creatorcontrib>Goodale, Amy</creatorcontrib><creatorcontrib>Persky, Nicole S</creatorcontrib><creatorcontrib>Root, David E</creatorcontrib><creatorcontrib>Cusick, Margaret</creatorcontrib><creatorcontrib>Ligon, Keith L</creatorcontrib><creatorcontrib>Beroukhim, Rameen</creatorcontrib><creatorcontrib>Phoenix, Timothy M</creatorcontrib><creatorcontrib>Rendo, Veronica</creatorcontrib><creatorcontrib>Bandopadhayay, Pratiti</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lupien, Leslie E</au><au>Morin, Eric</au><au>Zhang, Daren F</au><au>Novikov, Dana R</au><au>Chacon, Madison S</au><au>Khuu, Nicholas</au><au>Keshishian, Hasmik</au><au>Seidel, Olivia</au><au>Carr, Steven A</au><au>Goodale, Amy</au><au>Persky, Nicole S</au><au>Root, David E</au><au>Cusick, Margaret</au><au>Ligon, Keith L</au><au>Beroukhim, Rameen</au><au>Phoenix, Timothy M</au><au>Rendo, Veronica</au><au>Bandopadhayay, Pratiti</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DIPG-70. NQO1 AS A RESISTANCE DRIVER AND THERAPEUTIC TARGET IN DMG</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2024-06-18</date><risdate>2024</risdate><volume>26</volume><issue>Supplement_4</issue><spage>0</spage><epage>0</epage><pages>0-0</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>p53 pathway reactivation through pharmacologic inhibition of negative regulators was identified as a promising therapeutic strategy for TP53 wild-type (WT) high-grade gliomas, including Diffuse Midline Gliomas (DMGs). Despite widespread theoretical promise, the therapeutic efficacy of MDM2 inhibitors and PPM1D inhibitors as single agents have each been limited by issues, including sub-lethal effects on cancer cells and innate or emerging resistance leading to tumor progression. We carried out a genome-scale CRISPR activating (CRISPRa) screen to identify genes that, when overexpressed, confer resistance to p53 reactivation therapies. NAD(P)H quinone dehydrogenase 1 (NQO1) emerged as a top hit and was confirmed through secondary CRISPRa screens and low-throughput validations as driving a resistance phenotype in TP53 WT DMGs. Our subsequent work has aimed to elucidate the mechanisms through which NQO1 mediates the effects of p53 reactivation therapies, and assess the feasibility and impact of exploiting NQO1 in combination therapies towards a cure.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noae064.123</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1522-8517 |
| ispartof | Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (Supplement_4), p.0-0 |
| issn | 1522-8517 1523-5866 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11182908 |
| source | Oxford University Press Journals All Titles (1996-Current) |
| subjects | Final category: Diffuse Midline Glioma, Diffuse Intrinsic Pontine Glioma |
| title | DIPG-70. NQO1 AS A RESISTANCE DRIVER AND THERAPEUTIC TARGET IN DMG |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T10%3A20%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DIPG-70.%20NQO1%20AS%20A%20RESISTANCE%20DRIVER%20AND%20THERAPEUTIC%20TARGET%20IN%20DMG&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Lupien,%20Leslie%20E&rft.date=2024-06-18&rft.volume=26&rft.issue=Supplement_4&rft.spage=0&rft.epage=0&rft.pages=0-0&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noae064.123&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_11182908%3C/pubmedcentral_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |